Gilead Sciences Inc (GILD)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 78.26% | 77.98% | 77.62% | 77.71% | 77.99% | 78.81% | 79.42% | 79.17% | 79.26% | 74.62% | 75.59% | 75.74% | 75.82% | 80.45% | 80.14% | 80.58% | 81.48% | 79.02% | 78.57% | 79.37% |
| Operating profit margin | 28.97% | 29.63% | 36.40% | 33.14% | 31.34% | 30.16% | 30.95% | 32.68% | 24.54% | 19.78% | 23.16% | 23.98% | 36.32% | 42.31% | 36.74% | 17.83% | 16.49% | 10.86% | -4.33% | 19.60% |
| Pretax margin | 2.40% | 0.62% | 5.53% | 3.91% | 25.30% | 26.42% | 26.85% | 26.87% | 21.31% | 16.74% | 20.16% | 21.34% | 30.32% | 33.96% | 25.23% | 7.55% | 6.76% | 7.59% | -2.57% | 21.19% |
| Net profit margin | 1.67% | 0.45% | 3.79% | 1.76% | 20.89% | 21.45% | 20.03% | 20.64% | 16.81% | 12.26% | 15.01% | 16.41% | 22.80% | 26.90% | 19.38% | 1.18% | 0.50% | 5.48% | -1.16% | 21.84% |
Gilead Sciences Inc's profitability ratios have shown some fluctuations over the past few years.
1. Gross Profit Margin: The company's gross profit margin has generally been high, ranging from around 74% to 81% during the period. There was a slight decline towards the end of 2023 and into 2024.
2. Operating Profit Margin: Gilead Sciences Inc's operating profit margin has shown significant variability, with both positive and negative margins recorded. Despite some fluctuations, the margin improved over the years and peaked around mid-2021 before trending downwards towards the end of 2024.
3. Pretax Margin: The pretax margin has also fluctuated over the years, with some periods of significant increase in profitability. However, the margin dropped sharply at the end of 2023 and into 2024, indicating a decline in pre-tax profitability.
4. Net Profit Margin: The net profit margin has followed a similar trend to the pretax margin, showing fluctuations and a decline towards the end of 2023 and into 2024. Despite some periods of improvement, overall profitability seems to have decreased towards the latter part of the period.
In summary, while Gilead Sciences Inc has maintained relatively high gross profit margins, the operating, pretax, and net profit margins have shown more variability and a general decline towards the end of the period under review.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 14.12% | 15.38% | 18.89% | 16.16% | 13.68% | 13.24% | 13.59% | 14.28% | 10.60% | 8.58% | 10.14% | 10.45% | 14.60% | 17.33% | 14.40% | 6.75% | 5.95% | 4.13% | -1.72% | 7.45% |
| Return on assets (ROA) | 0.81% | 0.23% | 1.97% | 0.86% | 9.12% | 9.42% | 8.80% | 9.02% | 7.26% | 5.32% | 6.57% | 7.15% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% |
| Return on total capital | 8.63% | 6.26% | 13.75% | 11.64% | 34.30% | 36.67% | 39.19% | 39.13% | 31.83% | 26.07% | 32.20% | 34.37% | 44.05% | 48.27% | 39.25% | 15.46% | 14.57% | 15.55% | 2.23% | 26.13% |
| Return on equity (ROE) | 2.48% | 0.68% | 5.76% | 2.76% | 24.90% | 26.41% | 26.00% | 26.66% | 21.62% | 15.80% | 20.41% | 22.64% | 29.55% | 34.44% | 26.19% | 1.59% | 0.68% | 7.26% | -1.42% | 22.37% |
The profitability ratios of Gilead Sciences Inc show varying levels of performance over the analyzed period.
1. Operating Return on Assets (Operating ROA):
- Operating ROA experienced fluctuations ranging from negative values to a high of 18.89% by June 30, 2024. This ratio indicates the company's ability to generate profits from its operational activities relative to its assets.
- Gilead's Operating ROA generally improved over the period, showing signs of operational efficiency and effectiveness in utilizing its assets.
2. Return on Assets (ROA):
- ROA also had a mix of negative and positive values, with the highest point at 11.02% by September 30, 2021. ROA reflects the overall profitability of the company in generating earnings from its total assets.
- The trend in ROA suggests some challenges in generating profits relative to the size of the asset base, but there was a noticeable improvement towards the latter part of the period.
3. Return on Total Capital:
- Return on Total Capital ranged from 2.23% to 48.27%, showing a wide range of performance in utilizing both equity and debt to generate profits.
- The ratio indicates the efficiency of the company in generating returns for all capital sources, and Gilead's performance in this aspect showed variability over time.
4. Return on Equity (ROE):
- ROE fluctuated between negative values and highs of around 34.44% by September 30, 2021. ROE reflects the company's ability to generate profits for its shareholders from their equity investment.
- Gilead's ROE demonstrated some volatility throughout the period, with noticeable peaks and troughs, indicating fluctuations in the company's profitability.
In summary, Gilead Sciences Inc exhibited varying levels of profitability over the reported period, with improvements seen in certain ratios indicating enhanced operational efficiency and effectiveness in generating returns for its stakeholders. However, fluctuations and volatility in some ratios suggest ongoing challenges and areas where the company may need to focus on to sustain and enhance its profitability in the future.